AU2015276899B2 - Biomarkers for response to EZH2 inhibitors - Google Patents

Biomarkers for response to EZH2 inhibitors Download PDF

Info

Publication number
AU2015276899B2
AU2015276899B2 AU2015276899A AU2015276899A AU2015276899B2 AU 2015276899 B2 AU2015276899 B2 AU 2015276899B2 AU 2015276899 A AU2015276899 A AU 2015276899A AU 2015276899 A AU2015276899 A AU 2015276899A AU 2015276899 B2 AU2015276899 B2 AU 2015276899B2
Authority
AU
Australia
Prior art keywords
cancer
ezh2
bap1
biomarker
expression level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2015276899A
Other languages
English (en)
Other versions
AU2015276899A1 (en
Inventor
Omar Abdel-Wahab
Lindsay LAFAVE
Ross LEVINE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Memorial Sloan Kettering Cancer Center
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of AU2015276899A1 publication Critical patent/AU2015276899A1/en
Application granted granted Critical
Publication of AU2015276899B2 publication Critical patent/AU2015276899B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57575—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/91005—Transferases (2.) transferring one-carbon groups (2.1)
    • G01N2333/91011—Methyltransferases (general) (2.1.1.)
    • G01N2333/91017—Methyltransferases (general) (2.1.1.) with definite EC number (2.1.1.-)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7023—(Hyper)proliferation
    • G01N2800/7028—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2015276899A 2014-06-19 2015-06-19 Biomarkers for response to EZH2 inhibitors Ceased AU2015276899B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462014594P 2014-06-19 2014-06-19
US62/014,594 2014-06-19
PCT/US2015/036677 WO2015196064A1 (en) 2014-06-19 2015-06-19 Biomarkers for response to ezh2 inhibitors

Publications (2)

Publication Number Publication Date
AU2015276899A1 AU2015276899A1 (en) 2017-01-05
AU2015276899B2 true AU2015276899B2 (en) 2021-08-12

Family

ID=54936135

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015276899A Ceased AU2015276899B2 (en) 2014-06-19 2015-06-19 Biomarkers for response to EZH2 inhibitors

Country Status (15)

Country Link
US (1) US20170138946A1 (https=)
EP (1) EP3158086B1 (https=)
JP (1) JP6684230B2 (https=)
KR (1) KR20170020463A (https=)
CN (1) CN106795561B (https=)
AU (1) AU2015276899B2 (https=)
BR (1) BR112016029911A2 (https=)
CA (1) CA2952285A1 (https=)
EA (1) EA036889B1 (https=)
ES (1) ES2870096T3 (https=)
IL (1) IL249443B (https=)
MX (1) MX384423B (https=)
SG (2) SG11201610610YA (https=)
WO (1) WO2015196064A1 (https=)
ZA (1) ZA201608555B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230156450A (ko) 2012-10-15 2023-11-14 에피자임, 인코포레이티드 암을 치료하는 방법
WO2017035234A1 (en) 2015-08-24 2017-03-02 Epizyme, Inc. Method for treating cancer
TW201718598A (zh) 2015-08-27 2017-06-01 美國禮來大藥廠 Ｅｚｈ２抑制劑
CN109073659B (zh) 2016-02-16 2022-05-17 新加坡科技研究局 表观基因组分析揭示了原发性胃腺癌的体细胞启动子局面
GB201615842D0 (en) * 2016-09-16 2016-11-02 Ucl Business Plc Cell death biomarker
CN106963765B (zh) * 2017-03-28 2020-04-07 上海交通大学医学院附属第九人民医院 Ezh2抑制剂化合物在制备治疗眼部黑色素瘤的药物中的应用
WO2020247130A1 (en) * 2019-06-03 2020-12-10 Icahn School Of Medicine At Mount Sinai Compounds and methods for inhibiting cancers via rest inhibition
GB201919219D0 (en) 2019-12-23 2020-02-05 Otsuka Pharma Co Ltd Cancer biomarkers
CN118161615B (zh) * 2024-03-19 2025-08-12 山东大学齐鲁医院 Phf20抑制剂在制备抗皮肤癌药物中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012144220A1 (en) * 2011-04-22 2012-10-26 Oncotherapy Science, Inc. Ezh2 as target gene for cancer therapy and diagnosis
US20140011696A1 (en) * 2011-02-16 2014-01-09 Thomas Wiesner Bap1 mutational analysis in determining susceptibility to, prognosis of, and treatment of melanocytic neoplasia

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US548257A (en) 1895-10-22 Hay rake and loader
US5322770A (en) 1989-12-22 1994-06-21 Hoffman-Laroche Inc. Reverse transcription with thermostable DNA polymerases - high temperature reverse transcription
DE69132905T2 (de) 1990-12-06 2002-08-01 Affymetrix, Inc. (N.D.Ges.D.Staates Delaware) Detektion von Nukleinsäuresequenzen
US6379897B1 (en) 2000-11-09 2002-04-30 Nanogen, Inc. Methods for gene expression monitoring on electronic microarrays
US6465611B1 (en) 1997-02-25 2002-10-15 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
US5932422A (en) * 1997-11-14 1999-08-03 Millennium Pharmaceuticals, Inc. Modulation of drug resistance via ubiquitin carboxy-terminal hydrolase
US6218114B1 (en) 1998-03-27 2001-04-17 Academia Sinica Methods for detecting differentially expressed genes
US6004755A (en) 1998-04-07 1999-12-21 Incyte Pharmaceuticals, Inc. Quantitative microarray hybridizaton assays
US6218122B1 (en) 1998-06-19 2001-04-17 Rosetta Inpharmatics, Inc. Methods of monitoring disease states and therapies using gene expression profiles
US6406921B1 (en) 1998-07-14 2002-06-18 Zyomyx, Incorporated Protein arrays for high-throughput screening
US6271002B1 (en) 1999-10-04 2001-08-07 Rosetta Inpharmatics, Inc. RNA amplification method
US7429466B2 (en) 2000-01-24 2008-09-30 Hypromatrix, Inc Methods and arrays for detecting biological molecules
US6618679B2 (en) 2000-01-28 2003-09-09 Althea Technologies, Inc. Methods for analysis of gene expression
KR20030031911A (ko) 2001-04-19 2003-04-23 싸이퍼젠 바이오시스템즈, 인코포레이티드 질량 분석법과 친화성 태그를 이용한 생물분자 특성화
WO2003070887A2 (en) 2002-02-20 2003-08-28 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF POLYCOMB GROUP PROTEIN EZH2 GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP1390497A2 (en) 2001-05-25 2004-02-25 Genset Human cdnas and proteins and uses thereof
US7112408B2 (en) 2001-06-08 2006-09-26 The Brigham And Women's Hospital, Inc. Detection of ovarian cancer based upon alpha-haptoglobin levels
US20030013208A1 (en) 2001-07-13 2003-01-16 Milagen, Inc. Information enhanced antibody arrays
WO2003017177A2 (en) 2001-08-13 2003-02-27 Beyong Genomics, Inc. Method and system for profiling biological systems
US20030215858A1 (en) 2002-04-08 2003-11-20 Baylor College Of Medicine Enhanced gene expression system
WO2003091735A1 (en) 2002-04-23 2003-11-06 Millipore Corporation Sample preparation of biological fluids for proteomic applications
ES2511218T5 (es) 2005-06-20 2017-12-07 Advanced Cell Diagnostics, Inc. Kits y productos para detección de ácidos nucleicos en células individuales y para identificación de células raras en grandes poblaciones de células heterogéneas
WO2011103016A2 (en) 2010-02-19 2011-08-25 The Regents Of The University Of Michigan Compositions and methods for inhibiting ezh2
US9175331B2 (en) 2010-09-10 2015-11-03 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
BR112013005806B1 (pt) 2010-09-10 2022-05-10 Epizyme, Inc Métodos para detectar se um indivíduo é um candidato para o tratamento com ou responsivo a um inibidor de ezh2 e usos terapêuticos do dito inibidor de ezh2
CA2850570A1 (en) * 2011-09-30 2013-04-04 Glaxosmithkline Llc Methods of treating cancer
EP3536314A1 (en) 2012-03-12 2019-09-11 Epizyme, Inc. Inhibitors of human ezh2, and methods of use thereof
KR20230156450A (ko) 2012-10-15 2023-11-14 에피자임, 인코포레이티드 암을 치료하는 방법

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140011696A1 (en) * 2011-02-16 2014-01-09 Thomas Wiesner Bap1 mutational analysis in determining susceptibility to, prognosis of, and treatment of melanocytic neoplasia
WO2012144220A1 (en) * 2011-04-22 2012-10-26 Oncotherapy Science, Inc. Ezh2 as target gene for cancer therapy and diagnosis

Also Published As

Publication number Publication date
KR20170020463A (ko) 2017-02-22
JP2017525337A (ja) 2017-09-07
EP3158086A1 (en) 2017-04-26
IL249443B (en) 2022-05-01
MX384423B (es) 2025-03-14
SG10202007972SA (en) 2020-10-29
JP6684230B2 (ja) 2020-04-22
EP3158086B1 (en) 2021-03-24
EA036889B1 (ru) 2021-01-12
CN106795561B (zh) 2021-04-16
CA2952285A1 (en) 2015-12-23
BR112016029911A2 (pt) 2017-10-24
EA201692497A1 (ru) 2017-06-30
AU2015276899A1 (en) 2017-01-05
ZA201608555B (en) 2022-05-25
SG11201610610YA (en) 2017-01-27
WO2015196064A1 (en) 2015-12-23
EP3158086A4 (en) 2018-01-10
MX2016017097A (es) 2017-05-01
CN106795561A (zh) 2017-05-31
IL249443A0 (en) 2017-02-28
US20170138946A1 (en) 2017-05-18
ES2870096T3 (es) 2021-10-26

Similar Documents

Publication Publication Date Title
AU2015276899B2 (en) Biomarkers for response to EZH2 inhibitors
Fan et al. CircNR3C2 promotes HRD1-mediated tumor-suppressive effect via sponging miR-513a-3p in triple-negative breast cancer
Choi et al. YAP/TAZ initiates gastric tumorigenesis via upregulation of MYC
Gala et al. KMT2C mediates the estrogen dependence of breast cancer through regulation of ERα enhancer function
Boulding et al. LSD1 activation promotes inducible EMT programs and modulates the tumour microenvironment in breast cancer
Li et al. Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responses
LaFave et al. Loss of BAP1 function leads to EZH2-dependent transformation
CN103026227B (zh) 新的卵巢癌生物标志物和靶
Ye et al. Overexpression of CDCA7 predicts poor prognosis and induces EZH2‐mediated progression of triple‐negative breast cancer
Liu et al. C/EBPB-dependent adaptation to palmitic acid promotes tumor formation in hormone receptor negative breast cancer
McNee et al. Citrullination of histone H3 drives IL-6 production by bone marrow mesenchymal stem cells in MGUS and multiple myeloma
Che et al. Opposing transcriptional programs of KLF5 and AR emerge during therapy for advanced prostate cancer
Huang et al. METTL1 promotes neuroblastoma development through m7G tRNA modification and selective oncogenic gene translation
Shi et al. The previously uncharacterized lncRNA APP promotes prostate cancer progression by acting as a competing endogenous RNA
Huang et al. DDB2 is a novel regulator of Wnt signaling in colon cancer
Bai et al. Exo-miR-1290-induced by COX-2 overexpression promotes cancer-associated fibroblasts activation and tumor progression by CUL3-Nrf2 pathway in lung adenocarcinoma
Chen et al. CD146 promotes malignant progression of breast phyllodes tumor through suppressing DCBLD2 degradation and activating the AKT pathway
Shen et al. ALKBH4 functions as a suppressor of colorectal cancer metastasis via competitively binding to WDR5
Lv et al. Hsa_circ_0058495-mediated IGF2BP2 ubiquitination and m6A modification of MEKK1 promote the progression of PDAC
TW202122584A (zh) 預測癌症預後之方法及其應用
US8029989B2 (en) Method using snail transcriptional repressor
HK1230671B (en) Biomarkers for response to ezh2 inhibitors
EP3719137A1 (en) Ddx43 as a biomarker of resistance to mek1/2 inhibitors
Cui et al. Identification of differentially expressed genes associated with papillary thyroid carcinoma
Liu EZH2 Plays Distinct Roles in Tumor Initiation and Metastasis in Breast Cancer

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired